TFFP TFF Pharmaceuticals, Inc: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

TFF Pharmaceuticals (TFFP) has ceased operations and closed all projects, moving toward the sale of its intellectual property to settle liabilities. Current price action on GURU.Markets, where EV/EBITDA stands at , helps track this process. The business previously developed powder-based inhaled medications to eliminate the need for injections. Growth was constrained by strict FDA oversight, medical lobbying, and patent protection for freezing methods.

TFF Pharmaceuticals is optimizing costs by outsourcing the production of inhalation drugs to contract manufacturing organizations (CMOs), which eliminates the need for the company to own capital-intensive plants. This strategy directly impacts the EV/EBITDA calculation, which relates the total enterprise value to its operating profit before depreciation and interest. By analyzing the EV/EBITDA multiple trends on GURU.Markets, an investor determines the fairness of the asset's market price relative to its actual ability to generate cash flow.